|
Influenza
|
0.070 |
Biomarker
|
disease |
BEFREE |
Our results indicate the potential of the VLP vaccine approach in terms of immunogenicity but suggest that anti-HA immunity should not be considered as the sole preventive method for combatting influenza and postinfluenza bacterial infections.
|
31718898 |
2020 |
|
Influenza
|
0.070 |
Biomarker
|
disease |
BEFREE |
These results suggest that neuraminidase-presenting VLP can be developed as an effective cross-protective vaccine candidate along with current influenza vaccination.
|
31310875 |
2019 |
|
Influenza
|
0.070 |
Biomarker
|
disease |
BEFREE |
This work suggests that VLP vaccines incorporating conserved influenza virus proteins and GPI-anchored molecular adjuvants may serve as a platform for a broadly protective "universal" influenza vaccine.
|
30081250 |
2018 |
|
Influenza
|
0.070 |
Biomarker
|
disease |
BEFREE |
We tested whether virus-like particles presenting flagellin (Flag VLP) exhibit adjuvant effects on eliciting Th1 type immune responses and improving the efficacy of poor immunogenic tandem repeat M2e (M2e5x) protein vaccine against influenza virus.
|
30199754 |
2018 |
|
Influenza
|
0.070 |
Biomarker
|
disease |
BEFREE |
We previously reported the cross-protective efficacy of virus-like particle (M2e5x VLP) vaccines containing heterologous tandem M2e repeats (M2e5x) derived from human, swine, and avian influenza viruses.
|
29276514 |
2017 |
|
Influenza
|
0.070 |
Biomarker
|
disease |
BEFREE |
This study reports that H5 subtype consensus HA VLP single dose vaccination provides broad protection against HPAI virus in chickens.
|
29230222 |
2017 |
|
Influenza
|
0.070 |
Biomarker
|
disease |
BEFREE |
This review summarized the recent advancements in the research and development of influenza subunit and VLP vaccines based on the recombinant expression of hemagglutinin antigen (HA), neuraminidase antigen (NA), Matrix 2 protein (M2) and nucleocapsid protein (NP).
|
22684468 |
2012 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the immunogenicity, protection, and disease in mice after vaccination with RSV fusion protein (F) encoding plasmid DNA (F-DNA) or virus-like particles presenting RSV F (F-VLP).
|
31281715 |
2019 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.030 |
Biomarker
|
disease |
BEFREE |
Formalin-inactivated RSV (FI-RSV) vaccines and virus-like nanoparticles carrying RSV fusion proteins (F VLP) were investigated in mice.
|
29302248 |
2017 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we genetically inserted this epitope and multiple site variants of this epitope within a versatile woodchuck hepadnavirus core-based virus-like particle (WHcAg-VLP) to generate hybrid VLPs that each bears 240 copies of the RSV epitope in a highly immunogenic arrayed format.
|
25751145 |
2015 |
|
Lyme Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Additionally, both B. tachyglossi and B. turcica contain paralogous vsp and vlp proteins homologous to those used in the multiphasic antigen-switching system used by relapsing fever Borrelia to evade vertebrate immune responses, although their number was greatly reduced compared to human-infectious species.
|
30240834 |
2018 |
|
Lyme Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
This work developed a novel Lyme disease vaccine candidate by conjugating CspZ to VLP and eliminating FH-binding ability.
|
29472926 |
2018 |
|
Influenza A
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Anti-influenza A (H1N1) virus activity of these compounds was then evaluated using ribavirin as a positive control (IC<sub>50</sub> = 112.9 μM), revealing that compounds 11-14 showed considerable activity with IC<sub>50</sub> values of 112.7, 26.9, 106.7 and 28.8 μM, respectively, which are significantly improved as compared to that of VLP B (10) (IC<sub>50</sub> > 200 μM).
|
29650021 |
2018 |
|
Influenza A
|
0.020 |
Biomarker
|
disease |
BEFREE |
Developments of subunit and VLP vaccines against influenza A virus.
|
22684468 |
2012 |
|
Hepatitis E
|
0.020 |
Biomarker
|
disease |
BEFREE |
Delivery into mice of two HEV ORF2 genes via a papillomavirus VLP was very effective in the induction of anti-HEV antibodies.
|
18835319 |
2008 |
|
Hepatitis E
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this article, the recent advances of hepatitis E and the development of vaccine research for HEV including recombinant protein vaccine, DNA vaccine and the recombinant hepatitis E virus like particles (rHEV VLPs) are briefly reviewed.
|
15259057 |
2004 |
|
Superinfection
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In the present work, we assessed the off-target effects of a Tnms42 insect cell-expressed BEI-treated Gag-VLP preparation expressing the HA of A/Puerto Rico/8/1934 (H1N1) in preventing S. aureus superinfection in mice pre-infected with a homologous or heterologous H1N1 viral challenge strain.
|
31718898 |
2020 |
|
Post MI
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The ATRQβ-001 vaccine significantly reduced sudden cardiac death and increased survival rates (compared with MI + VLP, 80% versus 55% and mean estimate (days) 68.4 ± 7.0 versus 47.8 ± 8.9, respectively; p = 0.046) post MI.
|
30587854 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
For image-guided cancer phototherapy, indocyanine green (ICG) is loaded into RGD-HBc VLP via a disassembly/reassembly pathway and electrostatic attraction with high efficiency.
|
29786899 |
2018 |
|
Relapsing Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
Additionally, both B. tachyglossi and B. turcica contain paralogous vsp and vlp proteins homologous to those used in the multiphasic antigen-switching system used by relapsing fever Borrelia to evade vertebrate immune responses, although their number was greatly reduced compared to human-infectious species.
|
30240834 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
For image-guided cancer phototherapy, indocyanine green (ICG) is loaded into RGD-HBc VLP via a disassembly/reassembly pathway and electrostatic attraction with high efficiency.
|
29786899 |
2018 |
|
Anemia, Sickle Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
Results demonstrate that mice with SCD can respond to a VLP vaccine and to a respiratory virus challenge, encouraging rapid development of the B19 vaccine for patients with SCD.
|
28554503 |
2017 |
|
Poliomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.
|
28811473 |
2017 |
|
Teat papillomatosis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Thus, silkworm pupae are a useful bioreactor for the production of BPV6-VLP, which can potentially be used as a vaccine for bovine teat papillomatosis.
|
28893480 |
2017 |
|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
We designed the VLP immunogens which utilize hepatitis B virus core protein (HBcAg) as a carrier, and present arrays of the receptor-contacting epitopes of the human IgE on their surfaces.
|
25837568 |
2015 |